Seelos Therapeutics shares are trading lower after Guggenheim downgraded the stock from Buy to Neutral.
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics' stock has been downgraded from Buy to Neutral by Guggenheim, leading to a decrease in the company's share price.
September 22, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Seelos Therapeutics' stock was downgraded by Guggenheim, which has resulted in a decrease in the share price.
The downgrade of Seelos Therapeutics' stock by Guggenheim from Buy to Neutral indicates a less optimistic outlook for the company's stock, which can lead to selling pressure and a decrease in the stock price. This is directly relevant to the company and important for investors to note.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100